Thursday, 2 December 2021

Australia's most trusted
source of pharma news

Thursday, 02 December 2021

NY pharma registers first drug

Posted 22 November 2021 AM

New York-based Kadmon Holding's Australian subsidiary, Kadmon Oceania, registered Rholistiq - its first-ever product on the ARTG last week - for patients with chronic graft-versus-host disease (GVHD).

The therapy, marketed in the US under brand name Rezurock, was snapped up by Sanofi last month when it acquired Kadmon in a deal worth US$1.9 billion.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.